All News

Our cultural tendency to try to draw bright lines when it comes to the cost of health care relies on hindsight to criticize doctors for their lack of foresight. But it is only hindsight, as we all know, that is 20/20.

My last point of training was going to the San Antonio Breast Cancer Symposium (SABCS), which takes place the first week of December. It’s the biggest breast cancer symposium in the country and a chance for doctors, researchers and advocates to get together to hear the latest updates in research and clinical trials.

The FDA has approved Bosulif (bosutinib) as a first-line treatment for patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), based on findings from the phase 3 BFORE trial.

Cabometyx (cabozantinib) was granted approval by the Food and Drug Administration (FDA) for previously untreated patients who have advanced renal cell carcinoma (RCC).

Of every complication caused from cancer and its treatments, nausea has been the worst for my sister. It has caused pain, discomfort and was the number one reason she returned to the emergency room. No matter what medications were dosed, whether it was orally or by IV, or how much they gave to her, so often, nothing ever seemed to work.

Should I be planning big, celebratory trips or my funeral? My fears may not be rational, but they're real.

Why December is a good month to bug myself – and anyone in the Cancer Club – about changing it up.

Recent findings that the most common kind of ovarian cancer may start in the fallopian tubes could have implications for the prevention, diagnosis and treatment of the disease subtype.

Join us today, Dec. 19, for our year-end #CureConnect tweet chat, where we will be diving into what our readers saw as the most important updates of the year. Maybe people were intrigued by the correlation between viruses and cancer, or maybe improving cancer survivorship was key this year.

While the holidays can sometimes be a challenging time, there are always gifts to be found.

There are many ways to meditate, but I have learned there are some basic ways to support and promote healing by connecting with breath and mind. This aids in fighting feelings such as anxiety and depression when going through a cancer diagnosis.

Frontline Tagrisso (osimertinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) to treat patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations (exon 19 deletions or exon 21 [L858R] substitution mutations).

Setting resolutions for the New Year is a common practice but one breast cancer survivor has a different perspective on how hers should look for 2018.

I will remember my students' act of kindness forever.

Breast cancer and melanoma survivor shares ways to cope with fear of recurrence and cancer worries.

Patients with blood cancers typically value time spent at home in their end-of-life care, however, health care systemts do not always prioritize this in their own quality measures.

Statements to live by in making this time of year a little easier.

A team of six bicyclists trekked across country, from California to Connecticut, to fundraise for the Multiple Myeloma Research Foundation.

Could the cure for cancer be found in nature? The quest for a cure is the hope of every person touched by cancer. Perhaps the future cure will be found in a familiar Christmas plant.

Women with presumed uterine growths known as fibroids who underwent laparoscopic power morcellation (LPM) have higher rates of uterine cancer recurrence and worse outcomes compared to those who got manual or no morcellation, according to a recent release published by the Food and Drug Administration.

To raise awareness for the striking effects the disease has on women, the LCRF recently launched two campaigns.

Hoping that other women did not have to go through what she went through, in 1993 she co-founded the Alamo Breast Cancer Foundation (ABCF), a grassroots organization that helps patient advocates become educated on the disease – ultimately leading to more informed treatment decisions.

Frontline Opdivo (nivolumab) plus Yervoy (ipilimumab) was granted a priority review to a supplemental biologics license application (sBLA) to be used to treat patients with intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC).

Sometimes, cancer fear takes a back seat to magic.

Breast cancer survivor shares what happened when she found a new lump and got a genetic test result for PALB2.

No matter how cancer makes you look, you’re still you—a better you.

When it comes to advancements in treating blood cancers, 2017 was a particularly exciting year, with well over a dozen new therapies or indications approved by the Food and Drug Administration (FDA). The Leukemia & Lymphoma Society has played a role in at least 10 of these new drugs or medication uses at some point throughout their development and approval process.

To take the next step in this research, investigators are now combining immunotherapies together, or with chemotherapy, to create added benefits and more durable, long-lasting responses.